Actinium Pharmaceuticals

Company snapshot

Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tiss

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 20 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Actinium Pharmaceuticals. Not investment advice.

• Peer + 0 momentum

  Syndax Pharmaceuticals

  TA overlap score 29.4

• Peer + 0 momentum

  Shanghai Medical College

  TA overlap score 24

Recent activity

Latest pipeline, patent, and corporate events for Actinium Pharmaceuticals.

1. Jun 8, 2026 Clinical update

   Cytarabine (Phase 1 only) — Phase 2

2. Jun 5, 2026 Clinical update

   ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195 — Phase 1

3. May 23, 2026 Clinical update

   131I-apamistamab — Phase 3

4. May 23, 2026 Clinical update

   Iomab-B — Phase 3

5. May 23, 2026 Clinical update

   Iomab-B — Phase 2

View all clinical trial activity →

• What is Actinium Pharmaceuticals?

  Actinium Pharmaceuticals is a pharma organization headquartered in New York, USA. It trades on NYSE under ticker ATNM. Primary therapeutic focus areas include Acute Myeloid Leukemia, Acute Leukemia, Sickling Disorder Due to Hemoglobin S, Leukemia, Non Hodgkin Lymphoma. NovaPharma

• Is Actinium Pharmaceuticals publicly traded?

  Yes. Actinium Pharmaceuticals is listed with ticker ATNM on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Actinium Pharmaceuticals develop or market?

  We link 4 drug profile(s) where Actinium Pharmaceuticals is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/actinium-pharmaceuticals#company-drugs.

• What are the latest developments for Actinium Pharmaceuticals?

  In the last 12 months our linked public records show 8 trial program update(s) and 1 US patent grant(s) tied to this profile.

• What therapeutic areas does Actinium Pharmaceuticals focus on?

  Actinium Pharmaceuticals focuses on Acute Myeloid Leukemia, Acute Leukemia, Sickling Disorder Due to Hemoglobin S based on our analysis of their pipeline programs and drug development activities.